Drug Profile
H 40922
Alternative Names: H409/22Latest Information Update: 21 Sep 2000
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 21 Sep 2000 Discontinued-II for Ischaemic heart disorders in Europe (Unknown route)
- 28 Mar 2000 New profile
- 28 Mar 2000 Phase-II clinical trials for Ischaemic heart disorders in Europe (Unknown route)